MA29560B1 - Formulation a liberation prolongee de principes actifs de medicaments - Google Patents

Formulation a liberation prolongee de principes actifs de medicaments

Info

Publication number
MA29560B1
MA29560B1 MA30501A MA30501A MA29560B1 MA 29560 B1 MA29560 B1 MA 29560B1 MA 30501 A MA30501 A MA 30501A MA 30501 A MA30501 A MA 30501A MA 29560 B1 MA29560 B1 MA 29560B1
Authority
MA
Morocco
Prior art keywords
prolonged release
release formulation
active drug
drug principles
principles
Prior art date
Application number
MA30501A
Other languages
English (en)
Inventor
Gerard Alaux
Frederic Andre
Gareth Lewis
Veronique Serre
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29560(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA29560B1 publication Critical patent/MA29560B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE UNE NOUVELLE FORMULATION POUR UNE LIBÉRATION PROLONGÉE D'UN PRINCIPE ACTIF PRÉSENTANT UNE SOLUBILITÉ DÉPENDANTE DU PH. LA FORMULATION DE L'INVENTION COMPREND UN EXCIPIENT MATRICIEL À BASE DE POLYMÈRE HYDROPHILE RENFERMANT UNE DOSE DÉTERMINÉE DE PRINCIPE ACTIF, ET COMPREND ÉGALEMENT UN OU PLUSIEURS AGENTS ACIDIFIANTS SOUS FORME D'UN SEL ACIDE D'UN ACIDE ORGANIQUE.
MA30501A 2005-06-28 2007-12-24 Formulation a liberation prolongee de principes actifs de medicaments MA29560B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0506539A FR2887455B1 (fr) 2005-06-28 2005-06-28 Formulation a liberation prolongee de principes actifs de medicaments

Publications (1)

Publication Number Publication Date
MA29560B1 true MA29560B1 (fr) 2008-06-02

Family

ID=35708770

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30501A MA29560B1 (fr) 2005-06-28 2007-12-24 Formulation a liberation prolongee de principes actifs de medicaments

Country Status (30)

Country Link
US (1) US20080089936A1 (fr)
EP (1) EP1904037A1 (fr)
JP (1) JP2008546830A (fr)
KR (1) KR101387839B1 (fr)
CN (1) CN101217943B (fr)
AR (1) AR057410A1 (fr)
AU (1) AU2006264856B2 (fr)
BR (1) BRPI0612990A2 (fr)
CA (1) CA2611125A1 (fr)
CR (1) CR9567A (fr)
DO (1) DOP2006000144A (fr)
EA (1) EA013745B1 (fr)
EC (1) ECSP078010A (fr)
FR (1) FR2887455B1 (fr)
GT (1) GT200600275A (fr)
HN (1) HN2006023741A (fr)
IL (1) IL187901A0 (fr)
MA (1) MA29560B1 (fr)
MX (1) MX2007016238A (fr)
MY (1) MY150069A (fr)
NO (1) NO20080420L (fr)
NZ (1) NZ564069A (fr)
PA (1) PA8682701A1 (fr)
PE (1) PE20070098A1 (fr)
TN (1) TNSN07438A1 (fr)
TW (1) TWI446934B (fr)
UA (1) UA91553C2 (fr)
UY (1) UY29637A1 (fr)
WO (1) WO2007003746A1 (fr)
ZA (1) ZA200711035B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2090297A1 (fr) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formules de flibanserine
US20150024042A1 (en) * 2011-09-14 2015-01-22 Pozen Inc. Phased dosing of clopidogrel
IT201700011337A1 (it) * 2017-02-02 2018-08-02 S I I T S R L Servizio Int Imballaggi Termosaldanti Compressa multistrato per la somministrazione di magnesio

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
EP0701815B1 (fr) * 1992-01-17 1999-06-30 ALFATEC-PHARMA GmbH Procédé de préparation de poudres, granules ou pellets renfermant une substance active et ayant une structure composée de macromolécules hydrophiles, ainsi que leur utilisation
EP1005863A1 (fr) * 1998-12-04 2000-06-07 Synthelabo Formes galeniques a liberation controlee contenant un hypnotique a activite courte ou un sel de ce compose
AU3469100A (en) * 1999-01-05 2000-07-24 Copley Pharmaceutical Inc. Sustained release formulation with reduced moisture sensitivity
EP1064937A1 (fr) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Formes pharmaceutiques à liberation controllée comprenant un hypnotique à courte duree ou une des ses sels
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
JP2007510733A (ja) * 2003-11-05 2007-04-26 サンタラス インコーポレイティッド プロトンポンプ阻害剤および睡眠剤の併用

Also Published As

Publication number Publication date
ECSP078010A (es) 2008-01-23
UA91553C2 (ru) 2010-08-10
UY29637A1 (es) 2007-01-31
EA013745B1 (ru) 2010-06-30
CA2611125A1 (fr) 2007-01-11
MX2007016238A (es) 2008-03-06
EA200800150A1 (ru) 2008-04-28
US20080089936A1 (en) 2008-04-17
EP1904037A1 (fr) 2008-04-02
NO20080420L (no) 2008-01-22
DOP2006000144A (es) 2007-02-28
ZA200711035B (en) 2009-09-30
KR20080019023A (ko) 2008-02-29
NZ564069A (en) 2012-04-27
WO2007003746A1 (fr) 2007-01-11
CN101217943B (zh) 2012-05-23
JP2008546830A (ja) 2008-12-25
FR2887455B1 (fr) 2007-08-10
HN2006023741A (es) 2011-05-31
AU2006264856A1 (en) 2007-01-11
GT200600275A (es) 2007-03-29
TWI446934B (zh) 2014-08-01
TW200727921A (en) 2007-08-01
IL187901A0 (en) 2008-03-20
KR101387839B1 (ko) 2014-04-22
AR057410A1 (es) 2007-12-05
BRPI0612990A2 (pt) 2011-04-19
CR9567A (es) 2008-02-20
MY150069A (en) 2013-11-29
AU2006264856B2 (en) 2011-09-15
PA8682701A1 (es) 2007-01-17
HK1122731A1 (en) 2009-05-29
TNSN07438A1 (en) 2009-03-17
PE20070098A1 (es) 2007-03-01
CN101217943A (zh) 2008-07-09
FR2887455A1 (fr) 2006-12-29

Similar Documents

Publication Publication Date Title
WO2004033431A3 (fr) Hydroxypyrazoles et methodes prophylactiques ou de traitement de troubles lies au metabolisme
NO20071042L (no) 5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer
ATE523504T1 (de) 1-thio-d-glucitolderivate
MA29856B1 (fr) Derives de diacylindazole en tant qu'inhibiteurs de lipases et de phospholipases
EA200970726A1 (ru) Твердый препарат, содержащий алоглиптин и пиоглитазон
EA200701361A1 (ru) Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
LTPA2016042I1 (lt) 4[[4-[[4-(2-Cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska
MA30554B1 (fr) Malates et formes polymorphes de l'acide ( 3s,5s)-7-[3-amino-5-methyl-piperidinyl ]-1-cyclopropyl-1,4-dihydro-8- methoxy-4-oxo-3-quinoleine-carboxylique
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
CY1105479T1 (el) Παραγωγα τετραζολιου και μεθοδοι αντιμετωπισης σχετιζομενων με τον μεταβολισμο διαταραχων με αυτα
MY151470A (en) Controlled release solid preparation
MA29560B1 (fr) Formulation a liberation prolongee de principes actifs de medicaments
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
WO2005051937A3 (fr) Derives d'acide carboxylique 4-oxo-4,5-dihydrofurane-2 et methodes pour traiter des troubles du metabolisme
Luisi et al. New compounds for the management of Trypanosoma brucei infection
WO2007025764A3 (fr) Formulation pharmaceutique pour sels d'acides monobasiques avec du clopidogrel
WO2007052167A3 (fr) Formulation pharmaceutique
EA200701741A1 (ru) Композиция, содержащая окаперидон
TH103569A (th) อนุพันธ์ของ6-ไพริมิดินิล-ไพริมิด-2-โอน
BRPI0519840A2 (pt) derivados de ácido fenilbenzóico, processos para preparação do mesmo, composições farmacêuticas compreendendo-os e usos terapêuticos dos mesmos
TH79419A (th) วิธีรักษาการติดเชื้อ hiv
MA33080B1 (fr) Procede de preparation d'une composition pharmaceutique contenant en association la rifampicine, l'isoniazide, la pyrazinamide, et eventuellement l'ethambutol
TW200607498A (en) Agents for prevention or treatment of diseases associated with endothelial hyperproliferation
TN2013000022A1 (fr) Procede de preparation de comprimes contenant en association la firampicine, l'isoniazide, la pyrazinamide, et eventuellement l'ethambutol